Abstract
Summary
Risperidone(CAS：106266-06-2) is an atypical antipsychotic used to treat schizophrenia and bipolar disorder.
LPI (LP Information)' newest research report, the “Risperidone API Industry Forecast” looks at past sales and reviews total world Risperidone API sales in 2022, providing a comprehensive analysis by region and market sector of projected Risperidone API sales for 2023 through 2029. With Risperidone API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Risperidone API industry.
This Insight Report provides a comprehensive analysis of the global Risperidone API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Risperidone API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Risperidone API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Risperidone API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Risperidone API.
The global Risperidone API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Risperidone API players cover Interquim SA, Inke S.A, Jai Radhe Sales, Dr. Reddy's Laboratories, Mylan, Teva, RPG Life Sciences Ltd., Wuxi Jida Pharmaceutical Co., Ltd. and Venkata Narayana Active Ingredients, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Risperidone API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Above 98 %
Above 99 %
Segmentation by application
Tablets
Oral Solution
Capsules
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Interquim SA
Inke S.A
Jai Radhe Sales
Dr. Reddy's Laboratories
Mylan
Teva
RPG Life Sciences Ltd.
Wuxi Jida Pharmaceutical Co., Ltd.
Venkata Narayana Active Ingredients
Torrent Pharmaceuticals Limited
Zhejiang Huahai Pharmaceutical
Icrom
Jubilant Generics
Jeil Pharmaceutical Co., Ltd
Aurobindo Pharma Limited
Enaltec Labs Private Limited
Anugraha Chemicals
Otto Brandes
Aurore Life Sciences
Guangzhou Tosun Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Risperidone API market?
What factors are driving Risperidone API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Risperidone API market opportunities vary by end market size?
How does Risperidone API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Risperidone API Industry Forecast” looks at past sales and reviews total world Risperidone API sales in 2022, providing a comprehensive analysis by region and market sector of projected Risperidone API sales for 2023 through 2029. With Risperidone API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Risperidone API industry.
This Insight Report provides a comprehensive analysis of the global Risperidone API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Risperidone API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Risperidone API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Risperidone API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Risperidone API.
The global Risperidone API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Risperidone API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Risperidone API players cover Interquim SA, Inke S.A, Jai Radhe Sales, Dr. Reddy's Laboratories, Mylan, Teva, RPG Life Sciences Ltd., Wuxi Jida Pharmaceutical Co., Ltd. and Venkata Narayana Active Ingredients, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Risperidone API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Above 98 %
Above 99 %
Segmentation by application
Tablets
Oral Solution
Capsules
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Interquim SA
Inke S.A
Jai Radhe Sales
Dr. Reddy's Laboratories
Mylan
Teva
RPG Life Sciences Ltd.
Wuxi Jida Pharmaceutical Co., Ltd.
Venkata Narayana Active Ingredients
Torrent Pharmaceuticals Limited
Zhejiang Huahai Pharmaceutical
Icrom
Jubilant Generics
Jeil Pharmaceutical Co., Ltd
Aurobindo Pharma Limited
Enaltec Labs Private Limited
Anugraha Chemicals
Otto Brandes
Aurore Life Sciences
Guangzhou Tosun Pharmaceutical
Jiangsu Nhwa Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Risperidone API market?
What factors are driving Risperidone API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Risperidone API market opportunities vary by end market size?
How does Risperidone API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Risperidone API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Risperidone API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Risperidone API by Country/Region, 2018, 2022 & 2029
2.2 Risperidone API Segment by Type
2.2.1 Above 98 %
2.2.2 Above 99 %
2.3 Risperidone API Sales by Type
2.3.1 Global Risperidone API Sales Market Share by Type (2018-2023)
2.3.2 Global Risperidone API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Risperidone API Sale Price by Type (2018-2023)
2.4 Risperidone API Segment by Application
2.4.1 Tablets
2.4.2 Oral Solution
2.4.3 Capsules
2.4.4 Others
2.5 Risperidone API Sales by Application
2.5.1 Global Risperidone API Sale Market Share by Application (2018-2023)
2.5.2 Global Risperidone API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Risperidone API Sale Price by Application (2018-2023)
3 Global Risperidone API by Company
3.1 Global Risperidone API Breakdown Data by Company
3.1.1 Global Risperidone API Annual Sales by Company (2018-2023)
3.1.2 Global Risperidone API Sales Market Share by Company (2018-2023)
3.2 Global Risperidone API Annual Revenue by Company (2018-2023)
3.2.1 Global Risperidone API Revenue by Company (2018-2023)
3.2.2 Global Risperidone API Revenue Market Share by Company (2018-2023)
3.3 Global Risperidone API Sale Price by Company
3.4 Key Manufacturers Risperidone API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Risperidone API Product Location Distribution
3.4.2 Players Risperidone API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Risperidone API by Geographic Region
4.1 World Historic Risperidone API Market Size by Geographic Region (2018-2023)
4.1.1 Global Risperidone API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Risperidone API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Risperidone API Market Size by Country/Region (2018-2023)
4.2.1 Global Risperidone API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Risperidone API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Risperidone API Sales Growth
4.4 APAC Risperidone API Sales Growth
4.5 Europe Risperidone API Sales Growth
4.6 Middle East & Africa Risperidone API Sales Growth
5 Americas
5.1 Americas Risperidone API Sales by Country
5.1.1 Americas Risperidone API Sales by Country (2018-2023)
5.1.2 Americas Risperidone API Revenue by Country (2018-2023)
5.2 Americas Risperidone API Sales by Type
5.3 Americas Risperidone API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Risperidone API Sales by Region
6.1.1 APAC Risperidone API Sales by Region (2018-2023)
6.1.2 APAC Risperidone API Revenue by Region (2018-2023)
6.2 APAC Risperidone API Sales by Type
6.3 APAC Risperidone API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Risperidone API by Country
7.1.1 Europe Risperidone API Sales by Country (2018-2023)
7.1.2 Europe Risperidone API Revenue by Country (2018-2023)
7.2 Europe Risperidone API Sales by Type
7.3 Europe Risperidone API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Risperidone API by Country
8.1.1 Middle East & Africa Risperidone API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Risperidone API Revenue by Country (2018-2023)
8.2 Middle East & Africa Risperidone API Sales by Type
8.3 Middle East & Africa Risperidone API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Risperidone API
10.3 Manufacturing Process Analysis of Risperidone API
10.4 Industry Chain Structure of Risperidone API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Risperidone API Distributors
11.3 Risperidone API Customer
12 World Forecast Review for Risperidone API by Geographic Region
12.1 Global Risperidone API Market Size Forecast by Region
12.1.1 Global Risperidone API Forecast by Region (2024-2029)
12.1.2 Global Risperidone API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Risperidone API Forecast by Type
12.7 Global Risperidone API Forecast by Application
13 Key Players Analysis
13.1 Interquim SA
13.1.1 Interquim SA Company Information
13.1.2 Interquim SA Risperidone API Product Portfolios and Specifications
13.1.3 Interquim SA Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Interquim SA Main Business Overview
13.1.5 Interquim SA Latest Developments
13.2 Inke S.A
13.2.1 Inke S.A Company Information
13.2.2 Inke S.A Risperidone API Product Portfolios and Specifications
13.2.3 Inke S.A Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Inke S.A Main Business Overview
13.2.5 Inke S.A Latest Developments
13.3 Jai Radhe Sales
13.3.1 Jai Radhe Sales Company Information
13.3.2 Jai Radhe Sales Risperidone API Product Portfolios and Specifications
13.3.3 Jai Radhe Sales Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Jai Radhe Sales Main Business Overview
13.3.5 Jai Radhe Sales Latest Developments
13.4 Dr. Reddy's Laboratories
13.4.1 Dr. Reddy's Laboratories Company Information
13.4.2 Dr. Reddy's Laboratories Risperidone API Product Portfolios and Specifications
13.4.3 Dr. Reddy's Laboratories Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Dr. Reddy's Laboratories Main Business Overview
13.4.5 Dr. Reddy's Laboratories Latest Developments
13.5 Mylan
13.5.1 Mylan Company Information
13.5.2 Mylan Risperidone API Product Portfolios and Specifications
13.5.3 Mylan Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Mylan Main Business Overview
13.5.5 Mylan Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Risperidone API Product Portfolios and Specifications
13.6.3 Teva Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 RPG Life Sciences Ltd.
13.7.1 RPG Life Sciences Ltd. Company Information
13.7.2 RPG Life Sciences Ltd. Risperidone API Product Portfolios and Specifications
13.7.3 RPG Life Sciences Ltd. Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 RPG Life Sciences Ltd. Main Business Overview
13.7.5 RPG Life Sciences Ltd. Latest Developments
13.8 Wuxi Jida Pharmaceutical Co., Ltd.
13.8.1 Wuxi Jida Pharmaceutical Co., Ltd. Company Information
13.8.2 Wuxi Jida Pharmaceutical Co., Ltd. Risperidone API Product Portfolios and Specifications
13.8.3 Wuxi Jida Pharmaceutical Co., Ltd. Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Wuxi Jida Pharmaceutical Co., Ltd. Main Business Overview
13.8.5 Wuxi Jida Pharmaceutical Co., Ltd. Latest Developments
13.9 Venkata Narayana Active Ingredients
13.9.1 Venkata Narayana Active Ingredients Company Information
13.9.2 Venkata Narayana Active Ingredients Risperidone API Product Portfolios and Specifications
13.9.3 Venkata Narayana Active Ingredients Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Venkata Narayana Active Ingredients Main Business Overview
13.9.5 Venkata Narayana Active Ingredients Latest Developments
13.10 Torrent Pharmaceuticals Limited
13.10.1 Torrent Pharmaceuticals Limited Company Information
13.10.2 Torrent Pharmaceuticals Limited Risperidone API Product Portfolios and Specifications
13.10.3 Torrent Pharmaceuticals Limited Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Torrent Pharmaceuticals Limited Main Business Overview
13.10.5 Torrent Pharmaceuticals Limited Latest Developments
13.11 Zhejiang Huahai Pharmaceutical
13.11.1 Zhejiang Huahai Pharmaceutical Company Information
13.11.2 Zhejiang Huahai Pharmaceutical Risperidone API Product Portfolios and Specifications
13.11.3 Zhejiang Huahai Pharmaceutical Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Zhejiang Huahai Pharmaceutical Main Business Overview
13.11.5 Zhejiang Huahai Pharmaceutical Latest Developments
13.12 Icrom
13.12.1 Icrom Company Information
13.12.2 Icrom Risperidone API Product Portfolios and Specifications
13.12.3 Icrom Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Icrom Main Business Overview
13.12.5 Icrom Latest Developments
13.13 Jubilant Generics
13.13.1 Jubilant Generics Company Information
13.13.2 Jubilant Generics Risperidone API Product Portfolios and Specifications
13.13.3 Jubilant Generics Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Jubilant Generics Main Business Overview
13.13.5 Jubilant Generics Latest Developments
13.14 Jeil Pharmaceutical Co., Ltd
13.14.1 Jeil Pharmaceutical Co., Ltd Company Information
13.14.2 Jeil Pharmaceutical Co., Ltd Risperidone API Product Portfolios and Specifications
13.14.3 Jeil Pharmaceutical Co., Ltd Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Jeil Pharmaceutical Co., Ltd Main Business Overview
13.14.5 Jeil Pharmaceutical Co., Ltd Latest Developments
13.15 Aurobindo Pharma Limited
13.15.1 Aurobindo Pharma Limited Company Information
13.15.2 Aurobindo Pharma Limited Risperidone API Product Portfolios and Specifications
13.15.3 Aurobindo Pharma Limited Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Aurobindo Pharma Limited Main Business Overview
13.15.5 Aurobindo Pharma Limited Latest Developments
13.16 Enaltec Labs Private Limited
13.16.1 Enaltec Labs Private Limited Company Information
13.16.2 Enaltec Labs Private Limited Risperidone API Product Portfolios and Specifications
13.16.3 Enaltec Labs Private Limited Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Enaltec Labs Private Limited Main Business Overview
13.16.5 Enaltec Labs Private Limited Latest Developments
13.17 Anugraha Chemicals
13.17.1 Anugraha Chemicals Company Information
13.17.2 Anugraha Chemicals Risperidone API Product Portfolios and Specifications
13.17.3 Anugraha Chemicals Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Anugraha Chemicals Main Business Overview
13.17.5 Anugraha Chemicals Latest Developments
13.18 Otto Brandes
13.18.1 Otto Brandes Company Information
13.18.2 Otto Brandes Risperidone API Product Portfolios and Specifications
13.18.3 Otto Brandes Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Otto Brandes Main Business Overview
13.18.5 Otto Brandes Latest Developments
13.19 Aurore Life Sciences
13.19.1 Aurore Life Sciences Company Information
13.19.2 Aurore Life Sciences Risperidone API Product Portfolios and Specifications
13.19.3 Aurore Life Sciences Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Aurore Life Sciences Main Business Overview
13.19.5 Aurore Life Sciences Latest Developments
13.20 Guangzhou Tosun Pharmaceutical
13.20.1 Guangzhou Tosun Pharmaceutical Company Information
13.20.2 Guangzhou Tosun Pharmaceutical Risperidone API Product Portfolios and Specifications
13.20.3 Guangzhou Tosun Pharmaceutical Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Guangzhou Tosun Pharmaceutical Main Business Overview
13.20.5 Guangzhou Tosun Pharmaceutical Latest Developments
13.21 Jiangsu Nhwa Pharmaceutical
13.21.1 Jiangsu Nhwa Pharmaceutical Company Information
13.21.2 Jiangsu Nhwa Pharmaceutical Risperidone API Product Portfolios and Specifications
13.21.3 Jiangsu Nhwa Pharmaceutical Risperidone API Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Jiangsu Nhwa Pharmaceutical Main Business Overview
13.21.5 Jiangsu Nhwa Pharmaceutical Latest Developments
14 Research Findings and Conclusion